Boundless Bio Presents Preclinical Data for BBI-940 at AACR Annual Meeting 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Boundless Bio presents preclinical data supporting its lead ecDNA-directed therapy, BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, a potentially first-in-class, oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. "Extrachromosomal DNA is well established as a distinct enabler of chromosomal instability associated with oncogene amplification, therapeutic resistance, and poor outcomes for patients," said Chris Hassig, Chief Scientific Officer. "We have discovered and validated a novel kinesin target that plays a critical role in ecDNA segregation during cell division, thereby affording tumors with a high degree of genomic plasticity. Our data demonstrate that selective degradation of this target delivered potent antitumor activity in validated breast cancer models, particularly those with ecDNA. Our genetic, in vitro, in vivo, and toxicity profile of BBI-940 supports our recently initiated, first-in-human KOMODO-1 clinical trial evaluating BBI-940 in ER+/HER2- and TNBC-LAR breast cancer patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BOLD
Wall Street analysts forecast BOLD stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.500
Low
4.00
Averages
4.00
High
4.00
Current: 2.500
Low
4.00
Averages
4.00
High
4.00
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating the transaction between Dana Incorporated and Eaton Corporation, where Dana shareholders will own approximately 49.9% of the combined company upon closing, potentially impacting shareholder rights and options.
- Cash and Stock Deal: Element Solutions Inc is being sold to Solstice Advanced Materials for $10.00 in cash and 0.500 shares of Solstice common stock per Element share, with shareholders expected to own about 44% of the combined company, which may affect their investment returns.
- High Cash Acquisition: Nuvalent, Inc. is being sold to GSK plc for $124.00 per share in cash, providing significant cash returns to shareholders and potentially attracting more investor interest in the company.
- Merger Ownership Ratio: The merger between Boundless Bio, Inc. and Serapha Bio, Inc. is expected to leave Boundless Bio shareholders with only about 3.7% of the combined company, which may raise concerns among shareholders regarding the terms of the merger.
See More
Investigation Alerts for Multiple Company Mergers
- Element Solutions Acquisition: Element Solutions is set to be acquired by Solstice Advanced Materials in a deal where shareholders will receive $10.00 in cash and 0.500 shares of Solstice stock, totaling approximately $50.10 per share, with investigations into whether the Board breached fiduciary duties to ensure fair value for shareholders.
- Boundless Bio Merger: Boundless Bio will be acquired by Serapha Bio, with pre-merger Boundless shareholders expected to own about 3.7% of the combined entity, raising concerns over whether the Board failed to conduct a fair process to secure fair value for shareholders.
- Nuvalent Acquisition Deal: Nuvalent will be acquired by GSK for $124.00 per share in cash, valuing the deal at $10.6 billion, with investigations focusing on whether the Board breached fiduciary duties by not ensuring a fair transaction process for shareholders.
- Dana Merger Transaction: Dana will be acquired by Eaton Corporation in a deal valued at approximately $5.1 billion, with Eaton shareholders owning at least 50.1% post-merger, prompting investigations into whether the Board failed to conduct a fair process to secure fair value for shareholders.
See More
Investor Rights Law Firm Investigates Mergers
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Boundless Bio, Inc. and Serapha Bio, Inc., with Boundless Bio shareholders expected to own approximately 3.7% of the combined entity, potentially impacting shareholder rights and future returns.
- Legal Rights: The merger involving ENDRA Life Sciences Inc. and Noble Africa LLC is also under scrutiny, with ENDRA shareholders anticipated to hold about 3% of the new company, encouraging shareholders to understand their legal rights and options.
- Potential Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, raising questions about the merger terms and affecting shareholder decision-making and confidence.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations and commits to contingent fee arrangements, aiming to secure increased compensation and disclosures for affected shareholders, thereby protecting investor rights.
See More
Executives at Boundless Bio and Hallador Energy Increase Stock Holdings
- Executive Buying Activity: Kevin Tang of Boundless Bio purchased 286,333 shares of BOLD at $2.50 each on Monday, totaling an investment of $714,768, indicating his confidence in the company's future and potentially positively impacting the stock price.
- Market Reaction: Following Tang's purchase, Boundless Bio's stock rose approximately 2.4% on Tuesday, reflecting a positive market response to his buying activity and enhancing investor optimism regarding the company's prospects.
- Hallador Energy Transaction: On Thursday, Daniel Timothy Hudson bought 5,000 shares of Hallador Energy at $17.30 each, totaling $86,520, marking his first purchase in the past year and demonstrating his recognition of the company's value.
- Stock Performance: After Hudson's purchase, Hallador Energy's stock increased by about 1.8% on Tuesday, indicating a positive market reaction to his buying activity, which may attract more investor interest in the company.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating the transaction between Dana Incorporated and Eaton Corporation, where Dana shareholders will own approximately 49.9% of the combined company upon closing, potentially impacting shareholder rights and options.
- Cash and Stock Deal: Element Solutions Inc is being sold to Solstice Advanced Materials for $10.00 in cash and 0.500 shares of Solstice common stock per Element share, with shareholders expected to own about 44% of the combined company, which may affect their investment returns.
- High Cash Acquisition: Nuvalent, Inc. is being sold to GSK plc for $124.00 per share in cash, providing significant cash returns to shareholders and potentially attracting more investor interest in the company.
- Merger Ownership Ratio: The merger between Boundless Bio, Inc. and Serapha Bio, Inc. is expected to leave Boundless Bio shareholders with only about 3.7% of the combined company, which may raise concerns among shareholders regarding the terms of the merger.
See More
Investigation Alerts for Multiple Company Mergers
- Element Solutions Acquisition: Element Solutions is set to be acquired by Solstice Advanced Materials in a deal where shareholders will receive $10.00 in cash and 0.500 shares of Solstice stock, totaling approximately $50.10 per share, with investigations into whether the Board breached fiduciary duties to ensure fair value for shareholders.
- Boundless Bio Merger: Boundless Bio will be acquired by Serapha Bio, with pre-merger Boundless shareholders expected to own about 3.7% of the combined entity, raising concerns over whether the Board failed to conduct a fair process to secure fair value for shareholders.
- Nuvalent Acquisition Deal: Nuvalent will be acquired by GSK for $124.00 per share in cash, valuing the deal at $10.6 billion, with investigations focusing on whether the Board breached fiduciary duties by not ensuring a fair transaction process for shareholders.
- Dana Merger Transaction: Dana will be acquired by Eaton Corporation in a deal valued at approximately $5.1 billion, with Eaton shareholders owning at least 50.1% post-merger, prompting investigations into whether the Board failed to conduct a fair process to secure fair value for shareholders.
See More
Investor Rights Law Firm Investigates Mergers
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Boundless Bio, Inc. and Serapha Bio, Inc., with Boundless Bio shareholders expected to own approximately 3.7% of the combined entity, potentially impacting shareholder rights and future returns.
- Legal Rights: The merger involving ENDRA Life Sciences Inc. and Noble Africa LLC is also under scrutiny, with ENDRA shareholders anticipated to hold about 3% of the new company, encouraging shareholders to understand their legal rights and options.
- Potential Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, raising questions about the merger terms and affecting shareholder decision-making and confidence.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations and commits to contingent fee arrangements, aiming to secure increased compensation and disclosures for affected shareholders, thereby protecting investor rights.
See More
Executives at Boundless Bio and Hallador Energy Increase Stock Holdings
- Executive Buying Activity: Kevin Tang of Boundless Bio purchased 286,333 shares of BOLD at $2.50 each on Monday, totaling an investment of $714,768, indicating his confidence in the company's future and potentially positively impacting the stock price.
- Market Reaction: Following Tang's purchase, Boundless Bio's stock rose approximately 2.4% on Tuesday, reflecting a positive market response to his buying activity and enhancing investor optimism regarding the company's prospects.
- Hallador Energy Transaction: On Thursday, Daniel Timothy Hudson bought 5,000 shares of Hallador Energy at $17.30 each, totaling $86,520, marking his first purchase in the past year and demonstrating his recognition of the company's value.
- Stock Performance: After Hudson's purchase, Hallador Energy's stock increased by about 1.8% on Tuesday, indicating a positive market reaction to his buying activity, which may attract more investor interest in the company.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
